ISRG Margin Outlook Dips on Tariffs, Demand Signals Stay Strong

Intuitive Surgical (ISRG) reported strong Q1 2025 revenue growth of 19% to $2.25 billion, driven by increased da Vinci and Ion procedures; however, the company lowered its full-year gross margin guidance to 65-66.5% due to an estimated 170 basis point impact from higher U.S.-China tariffs on imported components. While ISRG maintains a robust $9 billion cash reserve and growing recurring revenue, the margin revision raises concerns about the company's cost structure resilience given its reliance on a global supply chain, especially compared to peers like Medtronic and Zimmer Biomet who are also facing tariff pressures but have more diversified operations.

Analysis

Intuitive Surgical (ISRG) reported robust top-line growth for the first quarter of 2025, with revenue increasing 19% year-over-year to $2.25 billion, fueled by a 17% rise in da Vinci procedures and a significant 58% surge in Ion procedures. Despite this strong demand, the company revised its full-year gross margin forecast downwards to 65%-66.5% from approximately 69.1% in 2024, citing an estimated 170 basis point negative impact from increased U.S.-China tariffs on imported components. This revision introduces near-term uncertainty regarding ISRG's traditionally consistent margins and highlights potential vulnerabilities in its cost structure, particularly given its reliance on a global supply chain for high-spec components for systems like the new da Vinci 5, with no current management plans for supply chain reshoring. Nevertheless, Intuitive Surgical's fundamental position remains strong, supported by a growing recurring revenue base, expanding procedure volumes, and a substantial $9 billion cash reserve, enabling continued investment in innovation. Comparatively, peers like Medtronic (MDT) and Zimmer Biomet (ZBH) also face tariff pressures; MDT anticipates a $200-$350 million net COGS impact in fiscal 2026 but benefits from a broad global manufacturing base, while ZBH expects a $60-$80 million tariff-related drag on 2025 operating profit but is actively implementing mitigation strategies. Year-to-date, ISRG shares have gained 1.5%, contrasting with the industry's 9.4% decline. The company trades at a forward price-to-sales ratio of 18.43, above the industry average yet below its five-year median of 19.23, and holds a Zacks Value Score of D. The Zacks Consensus Estimate for ISRG's 2025 earnings projects a 6.8% increase from the prior year.

Key Decisions for Investors

• Investors should weigh Intuitive Surgical's strong procedure-driven revenue growth and market leadership against the newly introduced gross margin pressures stemming from tariffs and its concentrated global supply chain.
• Monitor upcoming earnings reports for updates on margin trajectory, any implemented cost mitigation strategies, or potential adjustments to its supply chain to address tariff impacts.
• Evaluate the current valuation, considering the forward price-to-sales ratio and Value Score D, in the context of both the near-term margin headwinds and the company's long-term growth drivers, including its $9 billion cash reserve and commitment to innovation.
• Consider the relative resilience and diversification strategies of peers like Medtronic and Zimmer Biomet when assessing exposure to tariff-related risks within the medical device sector.